Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of
azacitidine，venetoclax，and flumatinib in newly diagnosed Philadelphia chromosome-positive
acute leukemia and accelerated phase or blast phase chronic myeloid leukemia patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University